Sitagliptin Placebo

DRUG5 trials

Sponsors

Sanofi, Amsterdam UMC, location VUmc, Takeda, Novo Nordisk A/S, NeuroBo Pharmaceuticals Inc.

Conditions

DiabetesDiabetes Mellitus, Type 2NON-ALCOHOLIC STEATOHEPATITISType 2 DiabetesType 2 Diabetes Mellitus

Phase 2

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

CompletedNCT06054815

NeuroBo Pharmaceuticals Inc.NON-ALCOHOLIC STEATOHEPATITIS

Start: 2023-09-14End: 2024-10-30Updated: 2024-11-14

Phase 3

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

CompletedNCT00976937

SanofiType 2 Diabetes Mellitus

Start: 2009-08-31End: 2011-03-31Updated: 2016-10-11

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

TerminatedNCT01834274

TakedaDiabetes Mellitus, Type 2

Start: 2013-06-30End: 2014-03-31Updated: 2015-09-28

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

CompletedNCT03061214

Novo Nordisk A/SDiabetes, Diabetes Mellitus, Type 2

Start: 2017-08-28End: 2019-04-15Updated: 2021-03-02

Phase 4

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

CompletedNCT01744236

Amsterdam UMC, location VUmcType 2 Diabetes

Start: 2013-04-30End: 2015-08-31Updated: 2015-12-09

Related Papers

Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes.

2024-01-184 citations

Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes

Diabetes & Metabolism2021-01-1259 citations

Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial.

2020-11-0720 citations

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Cardiovascular Diabetology2020-09-3056 citations

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

2016-09-15114 citations

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

2016-08-3046 citations

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Diabetologia2016-04-01124 citations

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

BMJ Open2015-11-0130 citations